Biotest Biotech

Biotest Biotech was founded in 2008 and is a national high-tech enterprise specializing in the research, development, manufacturing, sales, and service of in vitro diagnostic reagents, raw materials, and instruments. Biotest Biotech is committed to providing global users with innovative, instant, and high-quality diagnostic products and solutions to meet unmet medical needs. Currently, Biotest has about a hundred products, with business covering more than 100 countries and regions worldwide, serving over 3 billion people. Biotest products cover multiple fields of medical testing, including five major series: infectious disease testing, drug abuse (narcotics) testing, tumor marker testing, cardiac marker testing, and reproductive health testing, widely used in hospitals at all levels, disease control centers, blood stations, drug rehabilitation centers, and third-party testing institutions. The company has passed the German TUV ISO13485 quality management system certification, and many products have obtained China NMPA registration, EU CE certification, and U.S. FDA 510(k) clearance. Biotest Biotech emphasizes independent product research and development and technical accumulation, establishing an innovative and pioneering R&D team. The company owns industrial technology platforms such as a rapid immunoassay platform, POCT application technology platform, biological core raw material technology platform, and automated production technology platform, providing the enterprise with multiple patented technologies each year, along with the development and production of innovative products. The company has a marketing team with rich sales management experience, offering comprehensive professional services to end customers and channel partners.